Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury

• Yoon-Kyung Chang,

  Affiliations Department of Nephrology, Daejeon St. Mary Hospital, Daejeon, South Korea, Department of Nephrology, Catholic University of Korea, Seoul, South Korea

  ⨯
• Hyunsu Choi,

  Affiliation Clinical Research Institute, Daejeon St. Mary Hospital, Daejeon, South Korea

  ⨯
• Jin Young Jeong,

  Affiliations Department of Nephrology, School of medicine, Chungnam National University, Daejeon, South Korea, Department of Medical Science, School of medicine, Chungnam National University, Daejeon, South Korea

  ⨯
• Ki-Ryang Na,

  Affiliation Department of Nephrology, School of medicine, Chungnam National University, Daejeon, South Korea

  ⨯
• Kang Wook Lee,

  Affiliation Department of Nephrology, School of medicine, Chungnam National University, Daejeon, South Korea

  ⨯
• Beom Jin Lim ,

  Contributed equally to this work with: Beom Jin Lim, Dae Eun Choi

  * E-mail: daenii@cnu.ac.kr (DEC); bjlim@yuhs.ac (BJL)

  Affiliation Department of pathology, College of medicine, Yeonse University, Seoul, South Korea

  ⨯
• Dae Eun Choi

  Contributed equally to this work with: Beom Jin Lim, Dae Eun Choi

  * E-mail: daenii@cnu.ac.kr (DEC); bjlim@yuhs.ac (BJL)

  Affiliation Department of Nephrology, School of medicine, Chungnam National University, Daejeon, South Korea

  http://orcid.org/0000-0003-2870-3958

  ⨯